Ophthalmology CME

Filter
  • UNAVAILABLE

    ScientiaCME The roadmap to optimizing geographic atrophy care: updates in risk assessment, treatment, and care pathways in late-stage age-related macular degeneration

    Activity Description / Statement of Need:
    In this online, self-learning activity:

    Age-related macular degeneration (AMD) is the most common cause of blindness in individuals over the age of 50 years. In the early stages of disease, vision may be gray, hazy, or distorted. As the disease progresses, retinal deterioration can lead to irreversible, bilateral loss of central vision. In the US alone, an estimated 18.3 million people are living with early-stage ARMD, and 1.5 million people are living with late-stage AMD, representing 11.6% and 0.9% of all adults older than 40 years, respectively. In addition to the burden of disability caused by blindness, AMD is also associated with substantial societal and economic costs. In the US, vision loss and blindness incur an economic burden of $134 billion annually, of which $36 billion is attributable to indirect costs such as loss of productivity, injury, and unemployment.

    Target Audience:
    The following HCPs: comprehensive ophthalmologists and retinal specialists; physician assistants, and nurse practitioners who practice in ophthalmology; and any other HCPs with an interest in or who clinically encounter patients with AMD.

    See full details chevron_right
    • Credit hours: 1
    • CME credits awarded by: ScientiaCME
    • Format: On-Demand Online
    • Material last updated: September 16, 2023
    • Expiration of CME credit: September 16, 2025
    Full Details chevron_right
  • UNAVAILABLE

    Scientia CME – Staying Ahead of the Curve: Navigating the Rapid Advances in Myelin Oligodendrocyte Glycoprotein Antibody Disease (MOGAD)

    Myelin oligodendrocyte glycoprotein antibody disease (MOGAD) is a demyelinating, autoimmune condition affecting the central nervous system. MOGAD is characterized by the presence of autoantibodies directed against the MOG protein located on the surface of myelin sheaths surrounding nerve fibers in the CNS. The disease course may be monophasic or relapsing, and a progressive course is extremely rare, making the mortality rate fairly low (2.1%) compared to other neuroinflammatory diseases. It is a relatively new addition to the category of demyelinating diseases, and approximately 10,000 cases of MOGAD are estimated within the U.S.

    See full details chevron_right
    • Credit hours: 1
    • CME credits awarded by: ScientiaCME
    • Format: On-Demand Online
    • Material last updated: March 20, 2025
    • Expiration of CME credit: March 20, 2027
    Scientia CME Full Details chevron_right